Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dravet syndrome
Biotech
Stoke aims to restore developmental loss in Dravet syndrome
Stoke CEO Ian Smith said the company is seeing seizure reductions of up to 85% on top of standard-of-care medicines.
Gabrielle Masson
Mar 18, 2026 2:57pm
Encoded deciphers pivotal path with phase 1/2 gene therapy data
Dec 5, 2025 12:45pm
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Feb 18, 2025 9:28am
Encoded lays off 29% of staff to fund Dravet gene therapy trial
Feb 13, 2025 10:20am
Takeda axes epilepsy asset after FDA weighs in on data package
Jan 30, 2025 7:19am
Stoke's Dravet syndrome med released of partial clinical hold
Aug 7, 2024 8:54am
